Based on these trials, a meta-analysis comprising 38,723 individuals showed that SGLT2 inhibitor treatment in patients with type 2 diabetes was associated with an overall 32% reduction in hospitalisation for heart failure, whereas cardiovascular death was decreased by 17% and all-cause mortality by 15% [6]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.